- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/32 - Oxygen atoms
Patent holdings for IPC class C07D 209/32
Total number of patents in this class: 128
10-year publication summary
|
3
|
0
|
6
|
5
|
6
|
3
|
5
|
12
|
9
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1817 |
5 |
| Janssen Pharmaceuticals, Inc. | 442 |
4 |
| Katholieke Universiteit Leuven | 1227 |
4 |
| NovaTarg, Inc. | 5 |
4 |
| Terran Biosciences, Inc. | 96 |
3 |
| Bristol-myers Squibb Company | 4826 |
2 |
| Abbott Laboratories | 2357 |
2 |
| Centre National de La Recherche Scientifique | 10706 |
2 |
| Amira Pharmaceuticals, Inc. | 67 |
2 |
| Eisai R&D Management Co., Ltd. | 1204 |
2 |
| Avalyn Pharma Inc. | 35 |
2 |
| Actimed Therapeutics Limited | 30 |
2 |
| Techfields Inc | 10 |
2 |
| Advitech Advisory and Technologies SA | 4 |
2 |
| Enveric Biosciences Canada Inc. | 65 |
2 |
| Sintalica S.r.l. | 8 |
2 |
| Novartis AG | 10612 |
1 |
| Sandoz AG | 1411 |
1 |
| Boehringer Ingelheim International GmbH | 4636 |
1 |
| Ajinomoto Co., Inc. | 2310 |
1 |
| Other owners | 82 |